Gyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw strong trading volume on Monday . 32,014 shares were traded during trading, a decline of 56% from the previous session’s volume of 72,870 shares.The stock last traded at $13.05 and had previously closed at $12.84.

Gyre Therapeutics Stock Performance

The business’s 50 day simple moving average is $12.31 and its 200-day simple moving average is $14.40.

Insider Transactions at Gyre Therapeutics

In related news, Director Nassim Usman sold 3,452 shares of Gyre Therapeutics stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $12.00, for a total value of $41,424.00. Following the transaction, the director now directly owns 1,636 shares of the company’s stock, valued at $19,632. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.92% of the stock is currently owned by insiders.

Institutional Trading of Gyre Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. WINTON GROUP Ltd bought a new position in Gyre Therapeutics in the second quarter valued at about $220,000. Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter valued at approximately $218,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at approximately $166,000. Finally, Rhumbline Advisers acquired a new position in Gyre Therapeutics during the 2nd quarter worth approximately $123,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.